Actively Recruiting
Phase 23 Study to Test the Safety and Effectiveness of CM310 Injection for People Aged 12 to 75 with Moderate to Severe Asthma
Led by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Updated on 2023-12-15
600
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of CM310, a recombinant humanized monoclonal antibody injection, in people aged 12 to 75 with moderate to severe asthma. This multi-center, randomized, double-blind, placebo-controlled Phase 23 study aims to assess the drugs efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity. It focuses on improving asthma control and reducing severe exacerbations over one year. Participants are randomly assigned to one of three groups CM310 high dose, CM310 low dose, or placebo. CM310 is given as a subcutaneous injection with a loading dose initially, followed by doses every two weeks for a total of 26 doses during the 52-week treatment period. The study also includes a screening period of up to four weeks before treatment and a four-week safety follow-up after treatment ends. During the trial, participants undergo regular assessments including lung function tests like FEV1, symptom questionnaires such as the Asthma Control Questionnaire-5, and quality of life evaluations. Researchers monitor asthma exacerbations, hospital visits, medication use, and adverse events throughout the study. Blood samples are collected to analyze drug levels and immune responses. The total study duration for each participant is about 57 weeks including screening, treatment, and follow-up.
CONDITIONS
Brief Title
A Study of CM310 in Subjects With Moderate to Severe Asthma
Research Team
W
Wang Wenjuan
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here